Clinical trial · Observational
Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma
Predictive Value of Serum and Peritoneal CEA and CA 19-9 for TNM Stage and Peritoneal Dissemination of Gastric Adenocarcinoma
NCT02801955CI-TRIAL-00028111completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For preoperative staging and prediction of peritoneal dissemination of gastric adenocarcinoma, usage of serum and peritoneal levels of carcinoembryonic antigen (CEA) and CA 19-9 may be helpful. Additionally, the prognosis of the patients with gastric adenocarcinoma treated with gastrectrectomy may be associated with serum and peritoneal levels of tumor markers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| gastrectomy | Procedure | — | UNRESOLVED |
| sampling of peritoneal washing aspirate | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- tumor marker
- description
- serum CEA and CA 19-9 levels in patients with curative gastrectomy preoperatively and peritoneal CEA and CA 19-9 levels in patients taken at the beginning of curative gastrectomy via sampling of peritoneal washing aspirate
- interventionNames
- Procedure: gastrectomy
- Procedure: sampling of peritoneal washing aspirate
Primary outcomes (1)
- measure
- TNM stage
- timeFrame
- through pathologic report completion, an average of 1 month
- description
- TNM stage based on the 7th American Joint Committee on Cancer/International Union Against Cancer tumor, node, metastasis system.
Secondary outcomes (2)
- measure
- peritoneal washing cytology
- timeFrame
- through pathologic report completion, an average of 1 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Endoscopically proven gastric adenocarcinoma * Standard gastrectomy and a D2 lymph node dissection; * Desire to attend the study protocol Exclusion Criteria: * Metastatic or overt peritoneal disseminated cancer * Undesired reaction to attend the study protocol
References
Publications (0)
Data not yet available
No reference posted for this study.